BÜHLMANN Quantum Blue® Citations

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

August 21, 2018

Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663.

Read more

Quantum Blue® Adalimumab: Development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels

October 10, 2017
Quantum Blue® Infliximab Citation: F. I. Bantleon, S. Kräuchi, T. B. Schuster, M. Schneider, A. P. Abel Read Citation
Read more

The new infliximab point-of-care quantitative test can equally be used for therapeutic drug monitoring of biosimilars of infliximab

October 10, 2017
Quantum Blue® Infliximab Citation: J. Afonso, H.T. Sousa, I.Rosa, J.Carvalho, C. C. Dias, F. Magro on behalf GEDII Read Citation
Read more

Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease

May 22, 2017
BÜHLMANN Quantum Blue® fCAL extended Citation: Rodriguez, A. et al.  Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease. World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127. Highlight from this Publication “In summary, we present the first correlation study of rapid POC calprotectin testing in a pediatric IBD
Read more